Floatz logo

Enasidenib

AML Arising After Exposure to Genotoxic Injury

National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

78 Active assets in the AML Arising After Exposure to Genotoxic Injury cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Enasidenib is also rated in:

IDH2 Gene MutationDormant
BB
Indicative ·
64 / 100
View asset →
Isocitrate DehydrogenaseDormant
BB
Indicative ·
64 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →